An Advanced Tool To Interrogate BRD9.
Selective inhibitors of bromodomain-containing protein 9 (BRD9) may have therapeutic potential in the treatment of human malignancies and inflammatory diseases. A selective small molecule inhibitor that is well tolerated and has proper pharmacokinetic properties is required to explore the function of BRD9 in diseases. BI-9564 (2) is a cell permeable and noncytotoxic BRD9 inhibitor provided to the scientific community to explore BRD9 biology and determine its potential as a drug target.
Drug Discovery Department, Moffitt Cancer Center , Tampa, Florida 33612, United States.|Department of Molecular Medicine, University of South Florida , Tampa, Florida 33612, United States.
Rezaul M
RM
Karim
Drug Discovery Department, Moffitt Cancer Center , Tampa, Florida 33612, United States.|Department of Molecular Medicine, University of South Florida , Tampa, Florida 33612, United States.
Ernst
E
Schönbrunn
D001596:Benzylamines / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D009287:Naphthyridines / Q000737:chemistry / Q000494:pharmacology*; D054852:Small Molecule Libraries / Q000737:chemistry / Q000494:pharmacology*; D014157:Transcription Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000092468:Bromodomain Containing Proteins
D001596:Benzylamines; D009287:Naphthyridines; D054852:Small Molecule Libraries; D014157:Transcription Factors; C000619421:BI-9564; C587454:BRD9 protein, human; D000092468:Bromodomain Containing Proteins